Prosecution Insights
Last updated: October 02, 2026
Application No. 18/537,034

METHOD FOR PREPARING PARTIALLY FLUORINATED ALCOHOL

Final Rejection §102§103
Filed
Dec 12, 2023
Priority
Mar 21, 2019 — GB 1903909.8 +2 more
Examiner
CUTLIFF, YATE KAI RENE
Art Unit
1692
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Mexichem Fluor S A De C V
OA Round
2 (Final)
80%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 80% — above average
80%
Career Allowance Rate
1039 granted / 1302 resolved
+19.8% vs TC avg
Strong +24% interview lift
Without
With
+24.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 2m
Avg Prosecution
37 currently pending
Career history
1316
Total Applications
across all art units

Statute-Specific Performance

§101
3.9%
-36.1% vs TC avg
§103
38.8%
-1.2% vs TC avg
§102
13.0%
-27.0% vs TC avg
§112
34.3%
-5.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1302 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of Claims Clams 31 – 35 and 39 – 51 are pending. Claims 31 – 35, 39 – 41 and 46 – 51 are allowed. Claims 42 – 45 are rejected. Response to Amendment The amendment to claims 31 and 32, and new claims 41 - 51, submitted August 7, 2026 is acknowledged and entered. Response to Arguments Applicant’s arguments, see page 8, filed August 7, 2026, with respect to the rejection of claims 26 – 30, 37 and 38 under 35 USC 112(d) have been fully considered and are persuasive in view of the cancellation of the claims 26 – 30, 37 and 38. The rejection of claims 26 – 30, 37 and 38 has been withdrawn. Applicant’s arguments, see pages 8 - 10, filed August 7, 2026, with respect to the rejection of claims 26, 27, 28 and 31 are rejected under 35 U.S.C. § 102(a)(1) & (a)(2) as being anticipated by Terrell (US 3,862,240) have been fully considered and are persuasive in view of the cancellation of claims 26, 27, 28, amendment to claim 31 and arguments presented. The rejection of claims 26, 27, 28 and 31 under 35 U.S.C. § 102(a)(1) & (a)(2) has been withdrawn. Applicant’s arguments, see pages 8 - 10, filed August 7, 2026, with respect to the rejection of claim 27 is rejected under 35 U.S.C. § 102(a)(1) as being anticipated by Coe have been fully considered and are persuasive in view of the cancellation of claim 27. The rejection of claim 27 under 35 U.S.C. § 102(a)(1) has been withdrawn. Applicant’s arguments, see pages 8 - 10, filed August 7, 2026, with respect to the rejection of claim 27 is rejected under 35 U.S.C. § 102(a)(1) as being anticipated by Anderson have been fully considered and are persuasive in view of the cancellation of claim 27. The rejection of claim 27 under 35 U.S.C. § 102(a)(1) has been withdrawn. Applicant’s arguments, see pages 8 - 10, filed August 7, 2026, with respect to the rejection of claims 26, 27 and 31 are rejected under 35 U.S.C. § 102(a)(1) & (a)(2) as being anticipated by Chasbouni et al and Cheminform abs. have been fully considered and are persuasive in view of the cancellation of claims 26, 27, amendment to claim 31 and arguments presented. The rejection of claims 26, 27 and 31 under 35 U.S.C. § 102(a)(1) & (a)(2) has been withdrawn. Applicant’s arguments, see pages 8 - 10, filed August 7, 2026, with respect to the rejection of claims 27 – 30 under 35 USC 35 U.S.C. § 102(a)(1) & (a)(2) as being anticipated by Arthur have been fully considered and are persuasive in view of the cancellation of the claims 27 - 30. The rejection of claims 27 – 30 under 35 USC 35 U.S.C. § 102(a)(1) & (a)(2) has been withdrawn. Applicant’s arguments, see pages 8 - 10, filed August 7, 2026, with respect to the rejection of claim 32 under 35 USC 35 U.S.C. § 102(a)(1) & (a)(2) as being anticipated by Tapscott have been fully considered and are persuasive in view of the claim amendment. The rejection of claim 32 under 35 USC 35 U.S.C. § 102(a)(1) & (a)(2) has been withdrawn. Applicant’s arguments, see pages 8 - 10, filed August 7, 2026, with respect to the rejection of claim 32 under 35 USC 35 U.S.C. § 102(a)(1) & (a)(2) as being anticipated by Hudlicky have been fully considered and are persuasive in view of the claim amendment. The rejection of claim 32 under 35 USC 35 U.S.C. § 102(a)(1) & (a)(2) has been withdrawn. Applicant’s arguments, see pages 8 - 10, filed August 7, 2026, with respect to the rejection of claims 32, 33 and 35 under 35 USC 35 U.S.C. § 102(a)(1) & (a)(2) as being anticipated by Roberts have been fully considered and are persuasive in view of the claim amendment. The rejection of claims 32, 33 and 35 under 35 USC 35 U.S.C. § 102(a)(1) & (a)(2) has been withdrawn. Applicant’s arguments, see pages 8 - 10, filed August 7, 2026, with respect to the rejection of claim 32 and 33 under 35 USC 35 U.S.C. § 102(a)(1) as being anticipated by DiLoreto have been fully considered and are persuasive in view of the claim amendment. The rejection of claims 32 and 33 under 35 USC 35 U.S.C. § 102(a)(1) has been withdrawn. Applicant’s arguments, see pages 8 - 10, filed August 7, 2026, with respect to the rejection of claims 32, 33 and 34 under 35 USC 35 U.S.C. § 102(a)(1) as being anticipated by Bryantservt have been fully considered and are persuasive in view of the claim amendment. The rejection of claims 32, 33 and 34 under 35 USC 35 U.S.C. § 102(a)(1) has been withdrawn. Applicant’s arguments, see pages 10 - 12, filed August 7, 2026, with respect to the rejection of claims 26, 37 – 38, 31, 39 and 40 under 35 USC 112(a) have been fully considered and are persuasive in view of the cancellation of the claims 26, 37 – 38, amendment to claim 31, and arguments presented. The rejection of claims 26, 37 – 38, 31, 39 and 40 under 35 USC 112(a) has been withdrawn. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim(s) 42, 43 and 44 are rejected under 35 U.S.C. 102(a)(1) & (a)(2) as being anticipated by Sakata et al. (US 2014/0017560). The rejected claims cover, inter alia, the compound of PNG media_image1.png 242 506 media_image1.png Greyscale Independent claim 43 teaches a composition comprising the compound with the above structure. Independent claim 44 teaches a solvent composition comprising the compound with the above structure. However, Sakata discloses a lithium ion secondary cell containing a nonaqueous solvent such as the one below: PNG media_image2.png 138 518 media_image2.png Greyscale . See paragraph [0011] the fluorine-containing ether represented by the formula (I). The teaching of the solvent is discussed in paragraph [0008]). Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 42, 43 and 45 are rejected under 35 U.S.C. 103 as being unpatentable over Sakata et al. (US 2014/0017560), in view of Arthur et al. (WO2015/051131). Rejected clam 42 is disclosed in paragraph 20 above. Independent claim 43 teaches a composition comprising the compound with the above structure. Independent claim 44 teaches a coolant composition comprising a composition comprising the compound with the structure of paragraph 20. However, However, Sakata discloses a lithium ion secondary cell containing a nonaqueous solvent such as the one below: PNG media_image2.png 138 518 media_image2.png Greyscale . See paragraph [0011] the fluorine-containing ether represented by the formula (I). The teaching of the solvent is discussed in paragraph [0008]). According to the teaching of Sakata, their fluorine-containing ether is excellent for high temperature storage for the lithium ion of the lithium ion secondary cell. (Abstract, [0006] & [0018]). Sakata does not specifically state that their fluorine-containing ether is a coolant composition. However, Arthur states that fluorinated ethers have use as a heat transfer fluid, and as an electrolyte solvent in electrochemical cells, such as lithium ion batteries. (pp. 1, ln 14 – 15). As such, in this instance it would have been understood by one of ordinary skill in the art based on the teaching Arthur, that the capacity of the compound of Sakata to act as a coolant would be a natural feature of the compound. It is well settled that a patent cannot be properly granted for the discovery of a result which would flow naturally from the teaching of the prior art. In re Libby, 118, USPQ 94, 96; 255 F2d 412 (C.C.P.A. 1958) Allowable Subject Matter Claims 31 – 35, 39 – 41 and 46 – 51 are allowed. The following is a statement of reasons for the indication of allowable subject matter: the Examiner has considered the amendment filed by Applicant on August 7, 2026 and the arguments therein. Applicant’s arguments were found persuasive. Art Made of Record The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. US 5,536,885 (Hung) discloses production of perfluoro(alkyl vinyl ethers); and Fokin et al. ( Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya, 1977) discloses the reaction of polyfluorinated alcohols with fluoroolefins. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to YATE' K. CUTLIFF whose telephone number is (571)272-9067. The examiner can normally be reached Monday-Friday (8:30 - 5:30). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Scarlett Y. Goon can be reached at (571) 270-5241. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /YATE' K CUTLIFF/Primary Examiner, Art Unit 1692
Read full office action

Prosecution Timeline

Dec 12, 2023
Application Filed
May 28, 2026
Non-Final Rejection mailed — §102, §103
Aug 07, 2026
Response Filed
Sep 03, 2026
Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12747198
PHENOLIC ACID LIPID BASED CATIONIC LIPIDS
4y 0m to grant Granted Sep 29, 2026
Patent 12747256
METHOD FOR PRODUCING OXADISILACYCLOPENTANE COMPOUND
2y 10m to grant Granted Sep 29, 2026
Patent 12723014
REMOVAL OF SULFATE FROM MEG STREAMS USING CALCIUM CHLORIDE
2y 1m to grant Granted Sep 01, 2026
Patent 12715683
CONTAINER AND PROCESS FOR THE STORAGE OF A SATURATED ALIPHATIC C6-C12 CARBOXYLIC ACID
3y 4m to grant Granted Aug 25, 2026
Patent 12715835
BIORENEWABLE SYNTHESIS OF HYDROXY-HEXANOATE ESTERS
3y 0m to grant Granted Aug 25, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
80%
Grant Probability
99%
With Interview (+24.3%)
2y 2m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1302 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month